Herpes simplex virus DNA vaccine efficacy: effect of glycoprotein D plasmid constructs.
The impact of vaccination with plasmid DNA encoding full-length glycoprotein D (gD) from herpes simplex virus (HSV) type 2 (gD2), secreted gD2, or cytosolic gD2 was evaluated in mice and guinea pigs. Immunization with plasmids encoding full-length gD2 or secreted gD2 produced high antibody levels, whereas immunization with DNA encoding cytosolic gD2 resulted in significantly lower antibody titers in both species (P<.001). Vaccination with DNA encoding full-length or secreted gD2 significantly reduced acute disease in mice and guinea pigs (both P<.001) and subsequent recurrent disease in guinea pigs (P<.05). In guinea pigs, immunization with DNA encoding cytosolic gD2 did not protect from acute or recurrent disease, whereas in mice it did protect, but not as well as DNA encoding full-length or secreted gD2. None of the vaccines resulted in improved virus clearance from the inoculation site, and none significantly reduced recurrent disease when used as a therapeutic vaccine in HSV-2-infected guinea pigs.
Strasser
J E
JE
Division of Infectious Diseases, Children's Hospital Medical Center, Cincinnati, Ohio, USA. bernd0@chmcc.org
Arnold
R L
RL
Pachuk
C
C
Higgins
T J
TJ
Bernstein
D I
DI
D000818:Animals; D005260:Female; D006168:Guinea Pigs; D007114:Immunization; D051379:Mice; D010957:Plasmids; D018139:Simplexvirus / Q000276:immunology*; D019444:Vaccines, DNA / Q000276:immunology*; D014759:Viral Envelope Proteins / Q000235:genetics / Q000276:immunology*; D014765:Viral Vaccines / Q000276:immunology*
D019444:Vaccines, DNA; D014759:Viral Envelope Proteins; D014765:Viral Vaccines; C039447:glycoprotein D, Human herpesvirus 1